Since the start of the new year, more than 400 additional lawsuits relating to the medication Xarelto have been filed. The lawsuits allege that patients weren’t warned of the increased risk of bleeding associated with the medication.
Next generation anticoagulants like Xarelto have been marketed as easier to use than traditional anticoagulants because, unlike the older medications, they don’t require blood monitoring. However, many of these medications do not have an antidote, and a number of patients suffered hemorrhages and other serious bleeding events that could have been detected with regular blood monitoring.
Bellweather trials have been scheduled for early 2017, but it’s not too late for affected individuals to file suit. Currently, more than 3,000 lawsuits related to the medication are pending. The Xarelto manufacturers aren’t the only ones facing legal challenges; lawsuits have been filed against a number of newer-generation anticoagulant manufacturers for the same reason.